Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers

被引:46
作者
Ericsson, H [1 ]
Bredberg, U [1 ]
Eriksson, U [1 ]
Jolin-Mellgård, Å [1 ]
Nordlander, M [1 ]
Regårdh, CG [1 ]
机构
[1] AstraZeneca R&D, Expt Med, S-43183 Molndal, Sweden
关键词
arteriovenous; context-sensitive times; decrement times;
D O I
10.1097/00000542-200004000-00016
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Clevidipine is an ultra-short-acting calcium antagonist developed for reduction and control of blood pressure during cardiac surgery. The objectives of the current study were to determine the pharmacokinetics of clevidipine after 20-min and 24-h intravenous infusions, and to determine the relation between the arterial and venous concentrations and the hemodynamic responses to clevidipine in healthy volunteers. Methods: Four volunteers received clevidipine for 20 min, and eight subjects were administered clevidipine intravenously for 24 h at two different dose rates. Arterial and venous blood samples were drawn for pharmacokinetic evaluation, and blood pressure and heart rate were recorded. Results: A triexponential disposition model described the pharmacokinetics of clevidipine. The mean arterial blood clearance of clevidipine was 0.069 1 . kg(-1) . min(-1) and the mean volume of distribution at steady state was 0.19 1/kg. The duration of the infusion had negligible effect on the pharmacokinetic parameters, and the context-sensitive half-time for clevidipine, simulated from the mean pharmacokinetic parameters derived after 24 h infusion at the highest dose, was less than 1 min The arterial blood levels reached steady state within 2 min of the start of infusion and were about twice as high as those in the venous blood at steady state. The peak response preceded the peak venous concentration and was slightly delayed from the peak arterial blood concentration. Conclusion: Clevidipine is a high clearance drug with a small volume of distribution, resulting in extremely short half-lives in healthy subjects. The initial rapid Increase in the arterial blood concentrations and the short equilibrium time between the blood and the biophase suggest that clevidipine can be rapidly titrated to the desired effect.
引用
收藏
页码:993 / 1001
页数:9
相关论文
共 34 条
[1]   ARTERIAL-VENOUS NITROGLYCERIN GRADIENT DURING INTRAVENOUS-INFUSION IN MAN [J].
ARMSTRONG, PW ;
MOFFAT, JA ;
MARKS, GS .
CIRCULATION, 1982, 66 (06) :1273-1276
[4]   THE INFLUENCE OF INFUSION RATE ON THE HEMODYNAMIC-EFFECTS OF FELODIPINE [J].
COHEN, AF ;
VANHALL, MA ;
VANHARTEN, J ;
SCHOEMAKER, RC ;
JOHANSSON, P ;
BREIMER, DD ;
VISSER, R ;
EDGAR, B .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (03) :309-317
[5]   PHARMACOKINETICS, PHARMACODYNAMICS, AND MINIMUM EFFECTIVE CLINICAL DOSE OF INTRAVENOUS NICARDIPINE [J].
COOK, E ;
CLIFTON, GG ;
VARGAS, R ;
BIENVENU, G ;
WILLIAMS, R ;
SAMBOL, N ;
MCMAHON, G ;
GRANDY, S ;
LAI, CM ;
QUON, C ;
ANDERSON, CR ;
TURLAPATY, P ;
WALLIN, JD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (06) :706-718
[6]   PHARMACOKINETICS AND PHARMACODYNAMICS OF ATRACURIUM OBTAINED WITH ARTERIAL AND VENOUS-BLOOD SAMPLES [J].
DONATI, F ;
VARIN, F ;
DUCHARME, J ;
GILL, SS ;
THEORET, Y ;
BEVAN, DR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (05) :515-522
[7]   THE PHARMACOKINETICS OF THE NEW SHORT-ACTING OPIOID REMIFENTANIL (GI87084B) IN HEALTHY ADULT MALE-VOLUNTEERS [J].
EGAN, TD ;
LEMMENS, HJM ;
FISET, P ;
HERMANN, DJ ;
MUIR, KT ;
STANSKI, DR ;
SHAFER, SL .
ANESTHESIOLOGY, 1993, 79 (05) :881-892
[8]   In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man [J].
Ericsson, H ;
Tholander, B ;
Regårdh, CG .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 8 (01) :29-37
[9]   Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion [J].
Ericsson, H ;
Fakt, C ;
Höglund, L ;
Jolin-Mellgård, Å ;
Nordlander, M ;
Sunzel, M ;
Regårdh, CG .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (01) :61-67
[10]  
ERICSSON H, 1999, THESIS UPPSALA U